Condensed Interim Consolidated Financial Statements

Opsens Inc.

Six-month periods ended February 28, 2014 and 2013
(unaudited)

Notice

These unaudited condensed interim consolidated financial statements have not been reviewed by the Company's independent auditors.

Opsens Inc.

Six-month periods ended February 28, 2014 and 2013

Table of contents

Opsens Inc.

Interim Consolidated Statements of Loss and Comprehensive Loss
(unaudited)

	Three-month periods ended February 28,		Six-month periods ended February 28,	
	2014	**2013**	**2014**	**2013**
	$	**$**	**$**	**$**
Revenues				
Sales	**1,118,612**	1,836,766	**3,320,397**	4,369,515
Cost of sales	**744,150**	1,193,372	**2,146,075**	2,507,843
Gross margin	**374,462**	643,394	**1,174,322**	1,861,672
Expenses				
Administrative	**541,120**	610,661	**1,114,026**	1,149,290
Marketing	**211,122**	226,296	**505,522**	475,661
Research and development	**357,091**	424,000	**863,583**	811,382
Financial expenses	**108,430**	4,953	**219,517**	26,626
	1,217,763	1,265,910	**2,702,648**	2,462,959
Net loss and comprehensive loss	**(843,301)**	(622,516)	**(1,528,326)**	(601,287)
Net loss per share (note 6)				
Basic	**(0.02)**	(0.01)	**(0.03)**	(0.01)
Diluted	**(0.02)**	(0.01)	**(0.03)**	(0.01)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Opsens Inc.

Interim Consolidated Statements of Changes in Equity
Six-month period ended February 28, 2014
(unaudited)

	Common shares	Warrants	**Total**	Common shares	Reserve - Stock option plan	Reserve - Warrants	Deficit	**Total**
	(number)	(number)	**(number)**	$	$	$	$	**$**
Balance as at August 31, 2013	47,865,983	-	**47,865,983**	15,201,618	1,275,946	2,190,382	(15,274,768)	**3,393,178**
Common shares and warrants issued in connection with a public offering (note 5a)	11,504,520	3,475,426	**14,979,946**	7,412,867	-	126,485	-	**7,539,352**
Fair value of stock options exercised (note 5a)	-	-	**-**	38,080	(38,080)	-	-	**-**
Issued pursuant to the stock option plan (note 5a)	194,500	-	**194,500**	61,975	-	-	-	**61,975**
Stock-based compensation costs	-	-	**-**	-	108,202	-	-	**108,202**
Net loss	-	-	**-**	-	-	-	(1,528,326)	**(1,528,326)**
Balance as at February 28, 2014	59,565,003	3,475,426	**63,040,429**	22,714,540	1,346,068	2,316,867	(16,803,094)	**9,574,381**

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Opsens Inc.
Interim Consolidated Statements of Changes in Equity
Six-month period ended February 28, 2013
(unaudited)

	Common shares	Warrants	**Total**	Common shares	Reserve - Stock option plan	Reserve - Warrants	Deficit	**Total**
	(number)	(number)	**(number)**	$	$	$	$	**$**
Balance as at								
August 31, 2012	47,865,983	-	**47,865,983**	15,201,618	1,150,424	2,190,382	(12,908,943)	**5,633,481**
Stock-based compensation costs	-	-	**-**	-	54,915	-	-	**54,915**
Net loss	-	-	**-**	-	-	-	(601,287)	**(601,287)**
Balance as at								
February 28, 2013	47,865,983	-	**47,865,983**	15,201,618	1,205,339	2,190,382	(13,510,230)	**5,087,109**

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Opsens Inc.

Consolidated Statements of Financial Position

(unaudited)

	As at February 28, 2014	As at August 31, 2013
	$	$
Assets		
Current		
Cash and cash equivalents (note 8)	**10,009,669**	3,662,259
Trade and other receivables	**1,040,206**	959,857
Income tax credits receivable	**476,962**	565,086
Work in progress	**14,343**	55,491
Inventories	**3,001,643**	3,028,306
Prepaid expenses	**103,792**	187,672
	14,646,615	8,458,671
Property, plant and equipment	**1,092,201**	998,461
Intangible assets	**435,600**	394,421
Goodwill	**676,574**	676,574
	16,850,990	10,528,127
Liabilities		
Current		
Accounts payable and accrued liabilities	**1,628,704**	2,042,063
Warranty provision	**136,283**	144,783
Deferred revenues	**248,088**	51,188
Current portion of long-term debt	**173,823**	177,285
	2,186,898	2,415,319
Deferred revenues (note 3)	**2,002,000**	2,002,000
Long-term debt	**715,119**	587,819
Convertible debenture (note 4)	**2,372,592**	2,129,811
	7,276,609	7,134,949
Shareholders' equity		
Share capital	**22,714,540**	15,201,618
Reserve – Stock option plan	**1,346,068**	1,275,946
Reserve – Warrants	**2,316,867**	2,190,382
Deficit	**(16,803,094)**	(15,274,768)
	9,574,381	3,393,178
	16,850,990	10,528,127

Subsequent event (note 11)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Approved by the board

Signed [Jean Lavigueur] director

Signed [Louis Laflamme] director

Opsens Inc.

Interim Consolidated Statements of Cash Flows
(unaudited)

	Three-month periods ended February 28,		Six-month periods ended February 28,	
	2014	**2013**	**2014**	**2013**
	$	**$**	**$**	**$**
Operating activities				
Net loss before income taxes	**(843,301)**	(622,516)	**(1,528,326)**	(601,287)
Adjustments for:				
Depreciation of property, plant and equipment	**74,735**	70,981	**153,928**	131,296
Amortization of intangible assets	**10,567**	7,089	**21,345**	14,413
Stock-based compensation costs	**28,072**	24,184	**108,202**	54,915
Change in fair value of embedded derivative	**23,847**	2,691	**102,189**	2,691
Interest expense	**17,563**	11,494	**28,731**	19,189
Effect of foreign exchange rate changes on cash and cash equivalents	**45,162**	90,695	**51,724**	87,254
Unrealized foreign exchange loss	**94,379**	75,787	**111,427**	75,787
Government grants	**(11,922)**	-	**(122,730)**	-
Changes in non-cash operating working capital items (note 8)	**22,855**	(218,203)	**(540,057)**	777,456
	(538,043)	(557,798)	**(1,613,567)**	561,714
Investing activities				
Acquisition of property, plant and equipment	**(35,402)**	(218,915)	**(81,544)**	(349,088)
Additions to intangible assets	**(43,575)**	(15,496)	**(62,524)**	(26,080)
Interest received	**10,068**	-	**20,831**	-
	(68,909)	(234,411)	**(123,237)**	(375,168)
Financing activities				
Increase in long-term debt	**1,842**	59,951	**316,055**	189,700
Reimbursement of long-term debt	**(45,051)**	(43,428)	**(89,881)**	(97,029)
Proceeds from the issuance of the convertible debenture	**-**	-	**-**	2,002,000
Interest paid	**-**	(8,846)	**-**	(16,541)
Proceeds from issuance of shares and warrants (note 5a)	**8,544,479**	-	**8,567,079**	-
Share and warrants issue costs (note 5a)	**(657,315)**	-	**(657,315)**	-
	7,843,955	7,677	**8,135,938**	2,078,130
Effect of foreign exchange rate changes on cash and cash equivalents	**(45,162)**	(90,695)	**(51,724)**	(87,254)
Increase (decrease) in cash and cash equivalents	**7,191,841**	(875,227)	**6,347,410**	2,177,422
Cash and cash equivalents - beginning of period	**2,817,828**	5,629,235	**3,662,259**	2,576,586
Cash and cash equivalents – end of period	**10,009,669**	4,754,008	**10,009,669**	4,754,008

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Additional information is presented in note 8.

1. Incorporation and Description of Business

Opsens Inc. ("Opsens" or the "Company") is incorporated under the *Business Corporations Act* (Quebec). The Company is focusing on two main growth markets, Fractional Flow Reserve ("FFR") and oil and gas. The Company is also involved in industrial activities. Opsens develops, manufactures, supplies and installs systems for measuring a number of parameters, including pressure and temperature, using fiber optic sensing technologies. These systems are designed around patented technologies that are effective and durable in extreme conditions. The Company's head office is located at 125-2014, Cyrille-Duquet, Québec, Québec, Canada, G1N 4N6.

2. Basis of Preparation and Upcoming Revised Standards

Statement of Compliance

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as set out in the Canadian Institute of Chartered Accountants ("CICA") Handbook applicable to the preparation of interim financial statements, including International Accounting Standards ("IAS") 34, *Interim Financial Reporting* and using the same accounting policies and methods of computation as our most recent annual financial statements, except for the changes in accounting policies described below. These condensed interim consolidated financial statements should be read in conjunction with the annual financial statements for the year ended August 31, 2013, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board.

Changes in Accounting Policies

The Company adopted the following accounting policies on September 1, 2013.

IFRS 7 (Revised), Financial Instruments: Disclosures

On December 16, 2011, the International Accounting Standards Board ("IASB") and the Financial Accounting Standards Board ("FASB") issued common disclosure requirements that are intended to help investors and other users to better assess the effect or potential effect of offsetting arrangements on a company's financial position. The new requirements are set out in Disclosures-Offsetting Financial Assets and Financial Liabilities (Amendments to IFRS 7). New required interim note disclosures have been included in these condensed interim consolidated financial statements. The IFRS 7 amendments are effective for financial years beginning on or after January 1, 2013.

IFRS 10, Consolidated Financial Statements

IFRS 10, *Consolidated Financial Statements*, builds on existing principles by identifying the concept of control as the determining factor in whether an entity should be included within the consolidated financial statements of the parent company. The standard provides additional guidance to assist in the determination of control where this is difficult to assess. This standard replaces the Standing Interpretations Committee ("SIC") 12, *Consolidation – Special Purpose Entities* and parts of IAS 27, *Consolidated and Separate Financial Statements*.

The Company has concluded that the adoption of IFRS 10 did not result in any changes.

IFRS 11, Joint Arrangements

IFRS 11, *Joint Arrangements*, supersedes IAS 31, *Interests in Joint Ventures*, and requires joint arrangements to be classified either as joint operations or joint ventures, depending on the contractual rights and obligations of each investor that jointly control the arrangement. For joint operations, a company recognizes its share of assets, liabilities, revenues and expenses of the joint operation. An investment in a joint venture is accounted for using the equity method as set out in IAS 28, *Investments in Associates and Joint Ventures* (amended in 2011). The other amendments to IAS 28 did not affect the Company.

The Company has concluded that the adoption of IFRS 11 and IAS 28 (amended in 2011) did not result in any changes.

IFRS 12, Disclosure of Interest in Other Entities

IFRS 12, *Disclosure of Interests in Other Entities*, is a new and comprehensive standard on disclosure requirements for all forms of interests in other entities, including joint arrangements, associates, special purpose vehicles and other off balance sheet vehicles.

The Company assessed its disclosure of interest in other entities and determined that the adoption of IFRS 12 did not result in additional disclosures.

IFRS 13, Fair Value Measurement

IFRS 13, *Fair Value Measurement*, provides a single framework for measuring fair value. The measurement of the fair value of an asset or liability is based on assumptions that market participants would use when pricing the asset and liability under current market conditions, including assumptions about risk.

The adoption of this standard did not require any adjustments to the valuation techniques used by the Company to measure fair value and did not result in any measurement adjustments as at September 1, 2013.

IAS 34, Interim Financial Reporting

The Company has adopted the amendments to IAS 34, *Interim Financial Reporting,* effective September 1, 2013. These amendments required the Company to make the disclosures about the fair value of financial instruments required by IFRS 7, *Financial Instruments: Disclosures*, and IFRS 13, *Fair Value Measurement,* in its interim financial statements. The disclosures required by the adoption of IFRS 13 have been reflected in note 7 of these condensed interim consolidated financial statements.

3. Deferred Revenues

On November 19, 2012, the Company announced the granting of distribution and other rights for OptoWire and OptoMonitor, Opsens' products for measuring FFR. Under the terms of the agreement, the Company received:

- US$3 million for the distribution rights for its FFR products for Japan, Korea and Taiwan, which includes:
  a. US$2 million at signing ("upfront license fee");
  b. US$1 million once Opsens gets regulatory approval for its FFR devices in Japan ("milestone payment");
- US$2 million in convertible debenture, at signing, as described in note 4 of these condensed interim consolidated financial statements.

The Company shall reimburse the upfront license fee upon the occurrence of any of the following events:

a. The Company fails to obtain regulatory approval for the OptoWire and the OptoMonitor within five years of the agreement date for all the following geographic regions: Canada, European Union and the United States;

b. The Company abandons the development of the OptoWire and OptoMonitor before obtaining the milestone payment;

c. The Company materially breaches any terms of the agreement or is subject to bankruptcy.

Because the Company does not have regulatory approval, it has recorded the $2,002,000 (US$2,000,000) upfront license fee as deferred revenues.

The Company believes that the three conditions for a reimbursement of the upfront license fee listed above will not occur over the next twelve months. Consequently, the deferred revenues have been recorded in the long-term liabilities section of the consolidated statement of financial position.

4. Convertible Debenture

On November 19, 2012, the Company issued a US$2,000,000 ($2,002,000) subordinated secured convertible debenture maturing November 19, 2017. The convertible debenture bears interest at a rate of 2.0% per annum, payable at maturity. At the holder's option, the convertible debenture may be converted into common shares of the Company at any time up to the maturity date at a conversion price representing the market price of the shares. However, the conversion price is subject to a minimum of $0.50 and a maximum of $0.75 per common share (the "conversion price").

The convertible debenture is also convertible at the Company's option at the conversion price if the volume-weighted average closing price per common share for the twenty trading days immediately preceding the fifth trading day before such conversion date is at least $1.20 and if a minimum of 50,000 common shares have traded on the TSX Venture Exchange during each of the twenty trading days taken into account in the calculation of the conversion price.

To secure the repayment of the convertible debenture, a movable hypothec on certain equipment has been given. As at February 28, 2014, the net book value of property, plant and equipment pledged as collateral was $49,500 ($66,000 as at August 31, 2013). This hypothec will rank second to certain long-term loans of the Company.

As noted above, the convertible debenture contains a conversion option that will result in an obligation to deliver a fixed amount of equity in exchange of a variable amount of convertible debenture when translated into the functional currency of the Company. Consequently, under IAS 32, *Financial Instruments: Presentation*, the convertible debenture is accounted for as a compound instrument with a debt component and a separate embedded derivative representing the conversion option. Both the debt and embedded derivative components of this compound financial instrument are measured at fair value on initial recognition. The debt component is subsequently accounted for at amortized cost using the effective interest rate method. The embedded derivative is subsequently measured at fair value at each reporting date, with gains and losses in fair value recognized through profit or loss.

The carrying value of the convertible debenture and embedded derivative as of February 28, 2014 and August 31, 2013 is as follows:

	As of February 28, 2014	**As of August 31, 2013**
	$	**$**
Debt component reported as long-term liability (US$2,015,295 and US$1,990,316 as of August 31, 2013)	**2,229,184**	2,095,799
Embedded derivative reported as long-term liability (US$129,500 and US$32,300 as of August 31, 2013)	**143,408**	34,012
Total	**2,372,592**	2,129,811

5. Shareholders' Equity

a) Public offering and shares issued under the stock option plan

On February 18, 2014, the Company completed a public offering for aggregate gross proceeds of $8,505,104. In connection with the offering, the Company issued a total of 5,340,220 units at a price of $0.75 per unit and 6,164,300 common shares at a price of $0.73 per common share. Each unit consists of one common share in the capital stock of Opsens and one-half of one common share purchase warrant, with each whole common share purchase warrant entitling the holder thereof to purchase one common share at a price of $1.05 until February 17, 2016.

The value of one-half of one common share purchase warrant was established at $0.02, being the difference between the issuing price of $0.75 per unit and of $0.73 per common share. Expenses of the offering include 7% underwriting fees of $595,357 and other professional fees and miscellaneous fees of $370,396 for total fees of $965,753 of which $657,315 have been paid and $308,438 are included in accounts payable and accrued liabilities.

The Company also issued 805,316 broker warrants as additional compensation, each warrant entitling the holder to purchase one common share at a price of $0.73 until February 17, 2016. The total fees of $965,753 and the broker warrants value of $32,213 have been allocated on a prorata basis between share capital and the warrants reserve, $985,433 and $12,532 respectively, based on the ratio established by their respective values as described above.

During the six-month period ended February 28, 2014, following the exercise of stock options, the Company issued 194,500 common shares for a cash consideration of $61,975. The fair value of the stock options exercised was $38,080.

b) Warrants

The changes in the number of warrants issued by the Company and their weighted-average exercise prices, for the six-month period ended February 28, 2014, are as follows:

	Number of warrants	Weighted average exercise price
		$
Balance – Beginning of period	-	-
Warrants issued with units (note 5a)	2,670,110	1.05
Issued to brokers (note 5a)	805,316	0.73
Balance – End of period	3,475,426	0.98

c) Stock options

The changes in the number of options granted by the Company and their weighted-average exercise prices, for the six-month periods ended February 28, 2014 and 2013, are as follows:

	Six-month period ended February 28, 2014,		**Six-month period ended February 28, 2013,**	
	Number of options	**Weighted Average exercise price**	**Number of options**	**Weighted Average exercise price**
		$		**$**
Balance – Beginning of period	**4,141,667**	**0.27**	3,419,000	0.39
Exercised	**(194,500)**	**0.32**	-	-
Granted	**240,000**	**0.68**	1,433,667	0.24
Forfeited	**(50,000)**	**0.40**	(500,000)	0.72
Cancelled	**(506,667)**	**0.32**	(30,000)	0.20
Balance – End of period	**3,630,500**	**0.29**	4,322,667	0.51

6. Net Loss per Share

The table below presents a reconciliation between the basic net loss and the diluted net loss per share:

	Three-month periods ended February 28,		Six-month periods ended February 28,	
	2014	**2013**	**2014**	**2013**
	$	**$**	**$**	**$**
Net loss attributable to shareholders				
Basic and diluted	**(843,301)**	(622,516)	**(1,528,326)**	(601,287)
Number of shares				
Basic and diluted weighted average number of shares outstanding	**49,247,374**	47,865,983	**48,555,956**	47,865,983
Amount per share				
Net loss per share				
Basic	**(0.02)**	(0.01)	**(0.03)**	(0.01)
Diluted	**(0.02)**	(0.01)	**(0.03)**	(0.01)

Stock options and warrants are excluded from the calculation of the diluted weighted-average number of shares outstanding when their exercise price is greater than the average market price of common shares. The number of such stock options and warrants is presented below:

	Three-month periods ended February 28,		Six-month periods ended February 28,	
	2014	**2013**	**2014**	**2013**
Stock options	**150,000**	2,398,667	**150,000**	2,398,667
Warrants	**2,670,110**	-	**3,475,426**	-

For the three-month and six-month periods ended February 28, 2014 and 2013, the diluted amount per share was the same amount as the basic amount per share, since the dilutive effect of stock options, warrants and convertible debenture was not included in the calculation; otherwise, the effect would have been antidilutive. Accordingly, the diluted amount per share for this period was calculated using the basic weighted average number of shares outstanding.

7. Fair Value of Financial Instruments

The following table provides information about financial instruments measured at fair value in the statement of financial position and categorized by level according to the significance of the inputs used in making the measurements:

	Input level*	As of February 28, 2014 Fair Value and Carrying Value	As of August 31, 2013 Fair Value and Carrying Value
		$	$
Financial assets (liabilities) measured at fair value:			
Convertible debenture – embedded derivative	**2**	**(143,408)**	(34,012)

* Level 2 – Quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

The fair value of the embedded derivative financial instruments included in the convertible debenture is calculated using a financial model which includes observable data like share price and interest rates.

8. Statements of Cash Flows

	Three-month periods ended February 28,		Six-month periods ended February 28,	
	2014	**2013**	**2014**	**2013**
	$	**$**	**$**	**$**
Changes in non-cash operating working capital items				
Trade and other receivables	**768,229**	273,114	**(80,349)**	(574,280)
Income tax credits receivable	**(158,565)**	(85,446)	**88,124**	(167,915)
Work in progress	**(6,193)**	-	**41,148**	-
Inventories	**70,046**	(404,439)	**26,663**	(398,053)
Prepaid expenses	**45,598**	(106,650)	**83,880**	(98,554)
Accounts payable and accrued liabilities	**(788,529)**	12,218	**(887,923)**	(88,742)
Warranty provision	**-**	93,000	**(8,500)**	103,000
Deferred revenues	**92,269**	-	**196,900**	2,002,000
	22,855	(218,203)	**(540,057)**	777,456
Supplementary information				
Unpaid acquisition of property, plant and equipment	**166,126**	-	**166,126**	-
Unpaid share and warrants issue costs	**308,438**	-	**308,438**	-

	As of February 28, 2014	As of August 31, 2013
	$	**$**
Cash and cash equivalents		
Cash	**343,061**	687,881
Short-term investments	**9,666,608**	2,974,378
	10,009,669	3,662,259

9. Segmented information

Sector's Information

The Company's reportable segments are strategic business units managed separately as one is focused on developing, producing and supplying fiber optic sensors (Opsens Inc.) and the other (Opsens Solutions Inc.) is specialized in the commercialization and installation of optical and conventional sensors for the oil and gas industry.

The same accounting policies are used for both reportable segments. Operations are carried out in the normal course of operations and are measured at the exchange amount, which approximates prevailing prices in the markets.

	Three-month period ended February 28, 2014			Three-month period ended February 28, 2013		
	Opsens Inc.	**Opsens Solutions Inc.**	**Total**	Opsens Inc.	Opsens Solutions Inc.	Total
	$	**$**	**$**	$	$	$
External sales	**612,025**	**506,587**	**1,118,612**	359,297	1,477,469	1,836,766
Internal sales	**26,500**	**-**	**26,500**	428,388	-	428,388
Depreciation of property, plant and equipment	**41,418**	**33,317**	**74,735**	40,711	30,270	70,981
Amortization of intangible assets	**8,697**	**1,870**	**10,567**	5,691	1,398	7,089
Financial expenses (revenues)	**26,736**	**81,694**	**108,430**	(67,524)	72,477	4,953
Net loss	**(466,254)**	**(377,047)**	**(843,301)**	(609,516)	(13,000)	(622,516)
Acquisition of property, plant and equipment	**193,375**	**8,153**	**201,528**	70,685	148,230	218,915
Additions to intangible assets	**43,575**	**-**	**43,575**	15,496	-	15,496
Segment assets	**12,790,991**	**4,059,999**	**16,850,990**	7,322,299	4,058,423	11,380,722
Segment liabilities	**6,580,837**	**695,772**	**7,276,609**	5,635,726	657,887	6,293,613

	Six-month period ended February 28, 2014			Six-month period ended February 28, 2013		
	Opsens Inc.	**Opsens Solutions Inc.**	**Total**	Opsens Inc.	Opsens Solutions Inc.	Total
	$	**$**	**$**	$	$	$
External sales	**1,038,930**	**2,281,467**	**3,320,397**	1,023,540	3,345,975	4,369,515
Internal sales	**341,848**	**-**	**341,848**	625,180	-	625,180
Depreciation of property, plant and equipment	**87,349**	**66,579**	**153,928**	77,363	53,933	131,296
Amortization of intangible assets	**15,784**	**5,561**	**21,345**	11,613	2,800	14,413
Financial expenses (revenues)	**58,946**	**160,571**	**219,517**	(111,057)	137,683	26,626
Net earnings (loss)	**(1,273,242)**	**(255,084)**	**(1,528,326)**	(960,000)	358,713	(601,287)
Acquisition of property, plant and equipment	**234,402**	**13,268**	**247,670**	89,832	259,256	349,088
Additions to intangible assets	**60,253**	**2,271**	**62,524**	26,080	-	26,080
Segment assets	**12,790,991**	**4,059,999**	**16,850,990**	7,322,299	4,058,423	11,380,722
Segment liabilities	**6,580,837**	**695,772**	**7,276,609**	5,635,726	657,887	6,293,613

Geographic sector's information

	Three-month periods ended February 28,		Six-month periods ended February 28,	
	2014	**2013**	**2014**	**2013**
	$	**$**	**$**	**$**
Revenues per geographic sector				
Canada	**527,915**	**1,496,592**	2,318,127	3,387,016
United States	**261,754**	**102,912**	412,966	344,432
Others*	**328,943**	**237,262**	589,304	638,067
	1,118,612	**1,836,766**	3,320,397	4,369,515

* Comprise revenues generated in countries for which amounts are individually not significant.

Revenues are attributed to the geographic sector based on the clients' location. Capital assets, which include property, plant and equipment and intangible assets, are all located in Canada.

During the three-month period ended February 28, 2014, revenues from three clients represented individually more than 10% of the total revenues of the Company, i.e. approximately 34% (Opsens Solutions Inc.'s reportable segment), 12% (Opsens Inc.'s reportable segment) and 11% (Opsens Solutions Inc.'s reportable segment).

During the three-month period ended February 28, 2013, revenues from two clients represented individually more than 10% of the total revenues of the Company, i.e. approximately 63% (Opsens Solutions Inc.'s reportable segment) and 12% (Opsens Solutions Inc.'s reportable segment).

During the six-month period ended February 28, 2014, revenues from three clients represented individually more than 10% of the total revenues of the Company, i.e. approximately 26% (Opsens Solutions Inc.'s reportable segment), 25% (Opsens Solutions Inc.'s reportable segment) and 15% (Opsens Solutions Inc.'s reportable segment).

During the six-month period ended February 28, 2013, revenues from three clients represented individually more than 10% of the total revenues of the Company, i.e. approximately 43% (Opsens Solutions Inc.'s reportable segment), 18% (Opsens Solutions Inc.'s reportable segment) and 14% (Opsens Solutions Inc.'s reportable segment).

10. Approval of Condensed Interim Consolidated Financial Statements

The condensed interim consolidated financial statements were approved by the Board of Directors and authorized for issue on April 25, 2014.

11. Subsequent Event

On April 15, 2014, the Company announced it has entered into an agreement with Abiomed, Inc. ("Abiomed") in connection with its miniature optical pressure sensor technology for applications in circulatory assist devices. The Company has granted Abiomed an exclusive worldwide license to integrate its miniature pressure sensor in connection with Abiomed's circulatory assist devices. Under the agreement, Abiomed will pay Opsens an aggregate amount of US$6,000,000. US$1,500,000 is payable upon closing, while the balance will be disbursed based on the achievement of certain milestones, such as the meeting of certain performance requirements, the filing of regulatory application, the obtaining of regulatory approval and the transfer of manufacturing to Abiomed.

The closing payment of US$1,500,000 (CAN$1,647,150) will be recorded as a gain on disposal in the statement of loss. Future milestone payments will be recorded as gains on disposal when the conditions related to the payments will be met.